No Data
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"
No Data